Smith & Nephew (NYSE:SNN) and NanoVibronix (NASDAQ:NAOV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.
Institutional & Insider Ownership
9.0% of Smith & Nephew shares are owned by institutional investors. Comparatively, 13.4% of NanoVibronix shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by company insiders. Comparatively, 18.7% of NanoVibronix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Smith & Nephew and NanoVibronix’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Smith & Nephew||$4.77 billion||3.46||$767.00 million||$1.90||19.82|
Smith & Nephew has higher revenue and earnings than NanoVibronix.
Risk & Volatility
Smith & Nephew has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, NanoVibronix has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Smith & Nephew and NanoVibronix, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Smith & Nephew||0||4||2||0||2.33|
Smith & Nephew presently has a consensus price target of $42.00, indicating a potential upside of 11.55%. Given Smith & Nephew’s higher probable upside, research analysts plainly believe Smith & Nephew is more favorable than NanoVibronix.
Smith & Nephew pays an annual dividend of $0.54 per share and has a dividend yield of 1.4%. NanoVibronix does not pay a dividend. Smith & Nephew pays out 28.4% of its earnings in the form of a dividend.
This table compares Smith & Nephew and NanoVibronix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Smith & Nephew||N/A||N/A||N/A|
Smith & Nephew beats NanoVibronix on 9 of the 14 factors compared between the two stocks.
Smith & Nephew Company Profile
Smith & Nephew Plc engages in the development, manufacture, marketing, and sale of medical devices. It offers the following products and services: sports medicine joint repair; arthroscopic enabling technologies; trauma and extremities; other surgical businesses; knee and hip implants, and advanced wound care, wound bioactives, and wound devices. It operates through the United Kingdom, United States of America, and Other geographical segments. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.
NanoVibronix Company Profile
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.